# Study to Assess Safety and Tolerability of Multiple Doses of EO2002

> **NCT05636579** · PHASE1 · RECRUITING · sponsor: **Asociación para Evitar la Ceguera en México** · enrollment: 12 (estimated)

## Conditions studied

- Corneal Edema
- Corneal Endothelial Dystrophy
- Endothelial Dysfunction
- Fuchs Dystrophy
- Fuchs' Endothelial Dystrophy
- Bullous Keratopathy
- Pseudophakic Bullous Keratopathy
- Corneal Edema Pseudophakic

## Interventions

- **BIOLOGICAL:** EO2002
- **DRUG:** Ripasudil

## Key facts

- **NCT ID:** NCT05636579
- **Lead sponsor:** Asociación para Evitar la Ceguera en México
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-08
- **Primary completion:** 2025-12-09
- **Final completion:** 2025-12-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636579, "Study to Assess Safety and Tolerability of Multiple Doses of EO2002". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05636579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*